The Severe Acute Respiratory Syndrome, caused by a novel coronavlrus (SARS-CoV), resulted in substantial morbidity and mortality in 2002-2003. With the lack of recurrence of SARS, research efforts to understand pathogenesis and develop an effective vaccine have largely halted. However, coronaviruses similar to SARS-CoV have been identified in bats and other animal populations in China, making recurrence of SARS a possibility. Thus, we believe that efforts need to continue to understand pathogenesis and to develop vaccines and anti-viral therapies. In this PPG, several investigators with extensive experience in the pathogenesis, molecular biology and immunology of coronavirus infections will work together to better understand the interaction of SARS-CoV with the host respiratory tract and to develop novel approaches to preventing and treating SARS-CoV infections. These objectives will be investigated in the following projects. Project 1 will investigate severe disease in young BALB/c and aged BALB/c and C57BL/6 mice infected with mouse-adapted SARS-CoV and in SARS-CoV-infected mice that are transgenic for the human cellular receptor (angiotensin converting enzyme 2, hACE2). Project 2 will focus on the role of ACE2 signaling in pathogenesis. This project will also investigate the role of ACE2 by comparing cells and mice infected with SARS-CoV and HCoV-NL63, a common cold virus that also uses ACE2 to enter cells but does not cause severe disease. Project 3 will investigate the mechanism of action of two novel anti-virus therapies (rhesus theta defensin and griffithsin) and will investigate the role of ACE2 shedding in pathogenesis. Project 4 will develop and evaluate live attenuated SARS-CoV vaccines, based on the observation that virus deleted in the small envelope protein is viable, immunogenic and safe. All of the projects will use the Virology/Animal Models Core, which will engineer and propagate recombinant SARSCoV and will also analyze infected mice. Using the Core for these purposes will ensure reproducibility and ensure most effective use of our resources. These projects are all interrelated, will provide new information about SAR-CoV pathogenesis and will take advantage of the unique skills and expertise of the project directors.
The overall goal of this Program Project grant is to understand the pathogenesis of severe respiratory infections caused by the SARS-coronavirus and to develop and evaluate novel vaccines and anti-viral therapies that might be useful in future outbreaks.
|Channappanavar, Rudragouda; Fett, Craig; Mack, Matthias et al. (2017) Sex-Based Differences in Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Infection. J Immunol 198:4046-4053|
|Fehr, Anthony R; Channappanavar, Rudragouda; Perlman, Stanley (2017) Middle East Respiratory Syndrome: Emergence of a Pathogenic Human Coronavirus. Annu Rev Med 68:387-399|
|Park, Jung-Eun; Gallagher, Tom (2017) Lipidation increases antiviral activities of coronavirus fusion-inhibiting peptides. Virology 511:9-18|
|Zhao, Jingxian; Alshukairi, Abeer N; Baharoon, Salim A et al. (2017) Recovery from the Middle East respiratory syndrome is associated with antibody and T-cell responses. Sci Immunol 2:|
|Chi, Hang; Zheng, Xuexing; Wang, Xiwen et al. (2017) DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice. Vaccine 35:2069-2075|
|Morales, Lucía; Oliveros, Juan Carlos; Fernandez-Delgado, Raúl et al. (2017) SARS-CoV-Encoded Small RNAs Contribute to Infection-Associated Lung Pathology. Cell Host Microbe 21:344-355|
|Li, Kun; Wohlford-Lenane, Christine L; Channappanavar, Rudragouda et al. (2017) Mouse-adapted MERS coronavirus causes lethal lung disease in human DPP4 knockin mice. Proc Natl Acad Sci U S A 114:E3119-E3128|
|Fehr, Anthony R; Jankevicius, Gytis; Ahel, Ivan et al. (2017) Viral Macrodomains: Unique Mediators of Viral Replication and Pathogenesis. Trends Microbiol :|
|Tai, Wanbo; Wang, Yufei; Fett, Craig A et al. (2017) Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants. J Virol 91:|
|Zheng, Jian; Perlman, Stanley (2017) Immune responses in influenza A virus and human coronavirus infections: an ongoing battle between the virus and host. Curr Opin Virol 28:43-52|
Showing the most recent 10 out of 100 publications